The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Testman Thomas R since 2006.
The trader's CIK number is 1203841.
At the time of the last reporting, Testman Thomas R was the Director of Endocare Inc. (stock ticker symbol ENDO.PK).
Also see all insider trading activities at Endocare Inc.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2007 | AMLN | 0 | $0 | 32,000 | $1,456,980 | 32,000 | $534,559 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2009 | ENDO | 0 | $0 | 0 | $0 | 71,562 | $0 |
| 2007 | ENDO | 6,500 | $13,292 | 0 | $0 | 0 | $0 |
| 2006 | ENDO | 8,500 | $17,505 | 0 | $0 | 0 | $0 |
1. Amylin Pharmaceuticals Inc (AMLN)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2007-06-01 | AMLN | Option Ex | 12,000 | 16.23 | 194,760 |
| 2007-06-01 | AMLN | Sale | 12,000 | 46.62 | 559,380 |
| 2007-05-25 | AMLN | Option Ex | 20,000 | 16.99 | 339,799 |
| 2007-05-25 | AMLN | Sale | 20,000 | 44.88 | 897,600 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2009-07-27 | ENDO | Option Ex | 62,360 | .00 | 0 |
| 2009-05-15 | ENDO | Option Ex | 7,142 | .00 | 0 |
| 2009-01-10 | ENDO | Option Ex | 2,060 | .00 | 0 |
| 2007-08-16 | ENDO | Buy | 6,500 | 2.04 | 13,292 |
| 2006-08-29 | ENDO | Buy | 1,500 | 2.10 | 3,150 |
| 2006-08-25 | ENDO | Buy | 2,000 | 1.99 | 3,980 |
| 2006-08-28 | ENDO | Buy | 5,000 | 2.08 | 10,375 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Testman Thomas R (Director of Endocare Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.